Gianluca Pirozzi
Director/Board Member presso TREX WIND-DOWN, INC.
Patrimonio netto: 1 $ in data 31/03/2024
Profilo
Gianluca Pirozzi is an Independent Director at Timber Pharmaceuticals, Inc. since 2020 and a Senior VP, Head-Development, Regulatory & Safety at Alexion Pharmaceuticals, Inc. since 2019.
Previously, he worked as a Director at Imbria Pharmaceuticals, Inc. from 2018 to 2020 and as the Head-Rare Diseases at Genzyme Corp.
from 2018 to 2019.
He also held the position of Head-Gene Therapy at Genzyme Therapeutics Ltd.
Additionally, he served as the Head-Development for Rare Diseases & Gene Therapy at Sanofi SA from 2014 to 2019.
Dr. Pirozzi holds a doctorate degree from Sapienza University of Rome and Università Campus Bio-Medico di Roma.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
TREX WIND DOWN INC
0.10% | 07/09/2023 | 3 366 ( 0.10% ) | 1 $ | 31/03/2024 |
Posizioni attive di Gianluca Pirozzi
| Società | Posizione | Inizio |
|---|---|---|
| TREX WIND-DOWN, INC. | Director/Board Member | 01/05/2020 |
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/10/2019 |
Precedenti posizioni note di Gianluca Pirozzi
| Società | Posizione | Fine |
|---|---|---|
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director/Board Member | 01/05/2020 |
| Sanofi SA | Corporate Officer/Principal | 01/09/2019 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Formazione di Gianluca Pirozzi
| Sapienza University of Rome | Doctorate Degree |
| Università Campus Bio-Medico di Roma | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TREX WIND-DOWN, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
| Sanofi SA | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Gianluca Pirozzi
